Roopal Thakkar

New Capabilities

Leading AbbVie's immunology pipeline

Since 2022, adults with moderately to severely active Crohn's disease have started Skyrizi with three intravenous infusions at weeks 0, 4 and 8, usually at a clinic. On October 23, the Food and Drug Administration approved a second path: 720 milligrams injected under the skin at weeks 0, 2, 4 and 8, given at home with an on-body injector.

Updated Nov 1